Target intelligence / Profile preview

Ferrous iron in the labile iron pool (LIP)

Target
LIP
Molecular classification
Metal ion, Metabolite, Non-protein target
01

Overview

The ferrous iron in the labile iron pool (LIP) represents a transient, chelatable, and redox-active fraction of intracellular iron that is not tightly bound to storage proteins like ferritin (Kakalij et al., 2015). This pool is primarily composed of Fe2+ ions associated with low-molecular-weight ligands such as citrate, ATP, or glutathione, making it readily available for metabolic processes but also potentially hazardous (Espósito et al., 2002). Biologically, the LIP acts as a central junction for iron trafficking, providing the necessary metal for the biogenesis of heme and iron-sulfur clusters (Dixon et al., 2012). However, an expanded LIP can trigger the Fenton reaction, generating highly reactive hydroxyl radicals that cause lipid peroxidation and initiate ferroptosis, a regulated form of cell death (Stockwell et al., 2017). Therapeutic intervention typically involves iron chelators like Deferoxamine or Deferiprone, which sequester the ferrous iron to prevent oxidative damage in diseases such as thalassemia, hereditary hemochromatosis, and various neurodegenerative disorders (Mobarra et al., 2016).

Other names
Labile iron poolChelatable iron poolRedox-active ironIntracellular labile ironFree iron pool
02

Mechanism of action

Sequestration of redox-active ferrous iron through chelation, which prevents the iron from participating in the Fenton reaction and the subsequent generation of reactive oxygen species (ROS) and lipid peroxides (Mobarra et al., 2016).

03

Biological functions

Redox signalingIron homeostasisFenton reaction catalysisCofactor for iron-dependent enzymesFerroptosis induction (Dixon et al., 2012)Heme and iron-sulfur cluster synthesis
04

Disease associations

Iron overload (Thalassemia, Hemochromatosis)Neurodegenerative disease (Parkinson's, Alzheimer's)CancerIschemia-reperfusion injuryFerroptosis-related pathologies (Stockwell et al., 2017)
05

Safety considerations

Risk of systemic iron deficiency and anemiaNephrotoxicity (associated with Deferasirox)Ototoxicity and vision loss (associated with Deferoxamine)Agranulocytosis (associated with Deferiprone) (Mobarra et al., 2016)Gastrointestinal disturbances
06

Interacting drugs

Deferoxamine

5 more in the full profile.

07

Biomarkers

Calcein-AM fluorescence quenching (Espósito et al., 2002)Phen Green SK fluorescenceIntracellular ferritin levelsTransferrin saturation

Beyond the preview

Go deeper on Ferrous iron in the labile iron pool (LIP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ferrous iron in the labile iron pool (LIP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call